RxDoctor Payments Data

Charles Stevens, MD

Pain Medicine · El Centro, CANPI 1003001363

Payments from drug & device makers

$11,145in general payments, 2019–2025

Across 374 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$2K
  • Nevro Corp.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$892
  • Genesys Orthopedics Systems, L.L.C.$861
  • Medtronic$604
  • plus $3K from 36 others

What the payments were for

  • Travel & lodging$1,50313%
  • Food & beverage$9,60786%
  • Education$210%
  • Gifts$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,145 in reported general payments places this provider in the 80th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$500,577
Medicare patients
474
Services billed
7,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide91$217,088
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,711$52,746
MovantikNaloxegol Oxalate102$43,868
OxycontinOxycodone Hcl57$42,031
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen944$31,940
LinzessLinaclotide41$21,384
Xtampza ErOxycodone Myristate31$20,093
Lidocaine167$18,984
Naloxone Hcl288$18,768
Oxycodone Hcl730$15,603
Gabapentin1,301$15,199
Pregabalin547$14,764
Morphine Sulfate ErMorphine Sulfate486$13,051
Diclofenac Epolamine20$12,462
Fentanyl76$10,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$892$217,08891 claims
Redhill Biopharma Inc.Movantik$110$43,868102 claims
AbbVieLinzess$15$21,38441 claims
Collegium Pharmaceutical, Inc.Xtampza Er$266$20,09331 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine-Naloxone$44$11,664113 claims
MerckBelsomra$24$7,28217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 pain medicine providers in California.

Other pain medicine in El Centro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →